Please provide your email address to receive an email when new articles are posted on . Subtrochanteric fractures of the femur can challenge even the experienced surgeon and preoperative assessment ...

This interesting study shows that the incidence of more rare femoral fractures such as subtrochanteric fractures was stable from 1996 to 2006, although the overall incidence of hip fracture is ...

March 25, 2010 (UPDATED March 30, 2010) — Subtrochanteric and diaphyseal femur fractures are rare, even with bisphosphonate use for up to 10 years, according to the results of an analysis of 3 trials ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio The FDA has ruled out a suggested link ...

This page lists all known medications that could potentially lead to 'Subtrochanteric Femur Fracture' as a side effect. It's important to note that mild side effects are quite common with medications.

[03-10-2010] Patients and healthcare professionals may have questions about oral bisphosphonate medications and atypical subtrochanteric femur fractures - fractures in the bone just below the hip ...

A new position paper on "atypical" subtrochanteric fractures in association with long-term treatment with bisphosphonates examines available evidence which indicates that the proven benefits of ...

The agency says it will work with outside experts to gather more information. March 10, 2010— -- The U.S. Food and Drug Administration announced today that it will look into whether a link exists ...

(Corrects to show Actonel is owned by Warner Chilcott, 4th paragraph) * FDA says no thigh fracture risk with bisphosphonates * Bisphosphonates such as Fosamax treat osteoporosis * FDA statement ...

Atypical fractures of the femur associated with long-term bisphosphonate use can be distinguished by their distinct fracture pattern. These types of fractures generally are low-impact injuries that ...

Today, I had the privilege of observing the proceedings of the Food and Drug Administration Advisory Committee considering the benefits and risks of long-term bisphosphonate use for the treatment and ...

Bisphosphonate use is associated with only a very low risk of atypical fractures to the subtrochanteric or diaphyseal femur, even in women who receive the drugs for up to 10 years, data from an ...